Targeting KRAS-mutant NSCLC through inhibition of MTOR and Hsp90
Timothy F. Burns, MD, PhD
University of Pittsburgh Cancer Institute
Pittsburgh
Dr. Burns is working on targeted therapy for NSCLC patients with mutations in a gene called KRAS, using a new class of drugs.
Key words